S. Cousin

发表

CSF-1R Inhibitor Development: Current Clinical Status

A. Italiano, Florent Peyraud, S. Cousin, 2017, Current Oncology Reports.

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

A. Italiano, J. Guégan, Florent Peyraud, 2022, Frontiers in Immunology.

Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?

X. Buy, S. Cousin, J. Palussiere, 2019, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

D. de Ruysscher, D. Planchard, J. Adam, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.

N. Penel, A. Adenis, S. Cousin, 2012, Critical reviews in oncology/hematology.

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

N. Girard, D. Planchard, P. Dubray-Longeras, 2021, Targeted Oncology.

A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials

N. Penel, S. Taieb, S. Cousin, 2012, Current opinion in oncology.

Managing Endometrial Cancer: The Role of Pelvic Lymphadenectomy and Secondary Surgery

E. Leblanc, F. Narducci, E. Tresch, 2015, Annals of Surgical Oncology.

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

I. Soubeyran, A. Italiano, J. Soria, 2022, Journal for ImmunoTherapy of Cancer.

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.

N. Chaput, A. Marabelle, G. Roubaud, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical impact of extensive molecular profiling in advanced cancer patients

I. Soubeyran, Y. Laizet, M. Toulmonde, 2017, Journal of Hematology & Oncology.

PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)

S. Mathoulin-Pélissier, A. Italiano, N. Penel, 2016, BMC Cancer.

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial

J. Blay, J. Adam, M. Toulmonde, 2018, JAMA oncology.

Toxicity profiles of immunotherapy

A. Italiano, J. Seneschal, S. Cousin, 2018, Pharmacology & therapeutics.

Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities

A. Italiano, S. Cousin, 2016, Clinical Cancer Research.

Low skeletal muscle is associated with toxicity in patients included in phase I trials

V. Baracos, O. Mir, J. Soria, 2014, Investigational New Drugs.

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.

D. de Ruysscher, G. Bootsma, J. Mazières, 2019, European journal of cancer.

Ranking the most influential predictors of CT-based radiomics feature values in metastatic lung adenocarcinoma.

S. Nougaret, A. Crombé, M. Kind, 2022, European journal of radiology.

Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus.

A. Ravaud, C. Dupin, L. de Gabory, 2018, Oral oncology.

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.

J. Coindre, M. Toulmonde, A. Italiano, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.

D. Planchard, N. Chaput, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment.

A. Italiano, S. Cousin, D. Teyssonneau, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours.

A. Italiano, L. Leroy, S. Cousin, 2017, European journal of cancer.

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

J. Bonneterre, A. Duhamel, A. Awada, 2016, Pharmaceutical Medicine.

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

M. Toulmonde, A. Italiano, C. Bellera, 2022, Journal of Hematology & Oncology.

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study

X. Buy, M. Toulmonde, A. Italiano, 2022, Journal of Hematology & Oncology.

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

J. Blay, P. Terrier, O. Mir, 2017, BMC Medicine.

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

M. Toulmonde, A. Italiano, C. Bellera, 2022, Experimental Hematology & Oncology.

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

J. Blay, S. Litière, J. Verweij, 2018, OncoTarget.

Homogeneous myxoid liposarcomas mimicking cysts on MRI: A challenging diagnosis.

X. Buy, J. Coindre, M. Toulmonde, 2018, European journal of radiology.

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

I. Soubeyran, C. Sautès-Fridman, M. Toulmonde, 2021, Nature Cancer.

[Epithelioid hemangioendothelioma].

A. Crombé, F. Le Loarer, N. Penel, 2019, Bulletin du cancer.

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.

N. Girard, S. Novello, B. Besse, 2021, Clinical lung cancer.

Targeting ERBB2 mutations in solid tumors: biological and clinical implications

C. Lucchesi, I. Soubeyran, Y. Laizet, 2018, Journal of Hematology & Oncology.

Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.

N. Penel, S. Cousin, N. Kotecki, 2016, Critical reviews in oncology/hematology.

A Chatbot Versus Physicians to Provide Information for Patients With Breast Cancer: Blind, Randomized Controlled Noninferiority Trial

Alexandre Escande, Jean-Emmanuel Bibault, Sophie Cousin, 2019, Journal of medical Internet research.

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.

J. Blay, F. Bertucci, A. Cesne, 2019, European journal of cancer.

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.

J. Blay, E. Wardelmann, S. Litière, 2020, European journal of cancer.

Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors

N. Penel, N. Isambert, P. Cassier, 2015, Pharmaceutical Medicine.

Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.

I. Soubeyran, M. Toulmonde, A. Italiano, 2022, European journal of cancer.

Natural Speed of Growth of Untreated Soft-Tissue Sarcomas: a Dimension-Based Imaging Analysis

P. Spinnato, A. Crombé, M. Kind, 2021, European Journal of Radiology.

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

J. Blay, R. Plummer, G. Shapiro, 2021, International journal of cancer.

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

I. Soubeyran, A. Italiano, C. Bellera, 2021, Clinical Cancer Research.

Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors.

M. Toulmonde, A. Italiano, A. Crombé, 2020, European journal of radiology.

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

G. Shapiro, R. Prinjha, I. Braña, 2019, JNCI cancer spectrum.

MRI assessment of surrounding tissues in soft-tissue sarcoma during neoadjuvant chemotherapy can help predicting response and prognosis.

X. Buy, A. Italiano, A. Crombé, 2018, European journal of radiology.

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG "ANITA".

S. Litière, M. Toulmonde, H. Gelderblom, 2021, European journal of cancer.

CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications

C. Lucchesi, M. Toulmonde, A. Italiano, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

E. Felip, B. Cho, R. Knoblauch, 2021, Annals of Oncology.

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

I. Soubeyran, A. Italiano, T. Mazard, 2021 .

High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response

X. Buy, A. Italiano, A. Crombé, 2018, European Radiology.

Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.

E. Smit, M. Krzakowski, K. Goto, 2022, Journal of Clinical Oncology.

High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study

F. Bertucci, S. Chevret, A. Cesne, 2019, Annals of Oncology.

Feasibility of the sequential FEC 100-Taxotere chemotherapy regimen as an adjuvant or neoadjuvant treatment for breast cancer. Experience of a single institution.

L. Vanlemmens, S. Cousin, P. Vennin, 2009 .

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

I Judson, J Verweij, J. Blay, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

D. Hudry, N. Penel, F. Narducci, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).

B. Cho, F. Barlesi, T. Kim, 2020 .

Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival.

A. Duhamel, A. Kramar, N. Penel, 2013, Critical reviews in oncology/hematology.

Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group.

J. Blay, F. Bertucci, A. Italiano, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

N. Reinmuth, I. Horváth, K. Syrigos, 2022, The Lancet. Respiratory medicine.

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

F. Peale, G. Shapiro, P. LoRusso, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.

I. Soubeyran, M. Toulmonde, A. Italiano, 2020 .

Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.

J. Blay, A. Cesne, J. Adam, 2017 .

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.

J. Bonneterre, C. Fournier, É. Le Rhun, 2012, Bulletin du cancer.

PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

L. Paz-Ares, T. Ciuleanu, C. Grohé, 2021, Journal of Thoracic Oncology.

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

N. Girard, J. Mazières, P. Dubray-Longeras, 2022, European journal of cancer.

PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)

S. Mathoulin-Pélissier, A. Italiano, N. Penel, 2016, BMC Cancer.

Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.

F. Bertucci, S. Chevret, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

J. Bonneterre, A. Duhamel, A. Awada, 2016, Pharmaceutical Medicine.

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

J. Blay, F. Bertucci, S. Chevret, 2021 .

One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study

F. Durrieu, S. Mathoulin-Pélissier, I. Soubeyran, 2023, International journal of environmental research and public health.

Abstract LB-190: Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study

J. Blay, A. Cesne, J. Adam, 2017 .

Is There a Role for Percutaneous Ablation for Early Stage Lung Cancer? What Is the Evidence?

X. Buy, S. Cousin, J. Palussiere, 2021, Current Oncology Reports.

Diffuse cortical hypermetabolism of the cerebellum in meningeal carcinomatosis: Assessment with 18F-FDG-PET/CT and MRI.

A. Crombé, M. Kind, J. Bacci, 2019, Diagnostic and interventional imaging.

Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.

J. Blay, S. Mathoulin-Pélissier, M. Toulmonde, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

LBA67 TRAMUNE, a phase Ib study combining trabectedin and durvalumab, results of the expansion cohort in patients with advanced pretreated soft tissue sarcomas

J. Blay, S. Mathoulin-Pélissier, M. Toulmonde, 2020 .

Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting

S. Mathoulin-Pélissier, Anne-Laure Martin, C. Bellera, 2023, Scientific reports.

Genetic landscape of soft-tissue sarcomas: Moving toward personalized medicine.

C. Lucchesi, Y. Laizet, M. Toulmonde, 2017 .

RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.

E. Felip, D. Planchard, V. Ludovini, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

R. Dziadziuszko, J. Mazières, P. Garrido, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

J. Blay, S. Rodenhuis, G. Demetri, 2013 .

Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors

N. Penel, N. Isambert, P. Cassier, 2016, Pharmaceutical Medicine.

MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

C. Lefebvre, D. Ruysscher, D. Planchard, 2018, Journal of Thoracic Oncology.

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.

J. Blay, F. Bertucci, S. Chevret, 2023, The Lancet. Oncology.

[Epithelioid hemangioendothelioma].

A. Crombé, F. Le Loarer, N. Penel, 2019, Bulletin du cancer.